Coalition Covid-19 Brazil – Randomized trial: Azithromycin not beneficial for patients admitted to the hospital with severe Covid-19

Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial – The Lancet

Invited Commentary: Azithromycin for severe COVID-19

Commentaries on Twitter

This network of Brazilian researchers has done an AMAZING job of getting organized & answering important ?s. In this Lancet article they show in a randomized trial that #azithromycin does not improve #Covid19 outcomes. @RenatoDLopes1 https://t.co/zL7GSaVqm8

— C. Michael Gibson MD (@CMichaelGibson) September 5, 2020

New trial @TheLancet does not support the routine use of azithromycin in combination with #Hydroxychloroquine in patients with severe #COVIDー19:https://t.co/vaj1XX3dSo

— Madhu Pai (@paimadhu) September 6, 2020